Lowering ovarian cancer chemoresistance by NO/RNS involves, among others competition with cisplatin for the glutathione [71], decreasing activity of STAT3 and AKT signaling proteins [48,72], induction of DNA damage [50,51,52], inhibition of DNA repair protein activity [24,52,53], induction of apoptosis through, e.g., activation of p53 pathway, down-regulation of anti-apoptotic proteins or activation of Fas receptor [25,73]. The gene discussed is TP53; the disease is ovarian cancer.